This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Duan, J. Articles by Van Waes, C. Search for Related Content PubMed PubMed Citation Articles by Duan, J. Articles by Van Waes, C.

Research Articles: Therapeutics, Targets, and Development

Nuclear factor-B p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101

¹ Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland and ² CuraGen Corp., Branford, Connecticut

Requests for reprints: Carter Van Waes, National Institute on Deafness and Other Communication Disorders, NIH, CRC Building 10, Room 4-2732, 10 Center Drive, Bethesda, MD 20892. Phone: 301-402-4216; Fax: 301-402-1140. E-mail: vanwaesc{at}nidcd.nih.gov

Abstract

Histone deacetylase inhibitors (HDI) can inhibit proliferation and enhance apoptosis in a wide range of malignancies. However, HDIs show relatively modest activity in head and neck squamous cell carcinomas (HNSCC), in which we have shown the activation of nuclear factor-B (NF-B; NF-B1/RelA or p50/p65), a transcription factor that promotes expression of proliferative and antiapoptotic genes. In this study, we examined if HDIs enhance activation of NF-B and target genes and if genetic or pharmacologic inhibition of NF-B can sensitize HNSCC to HDIs. Limited activity of classic HDIs trichostatin A and sodium butyrate was associated with enhanced activation of NF-B reporter activity in a panel of six HNSCC cell lines. HDIs enhanced NF-B p50/p65 DNA binding and acetylation of the RelA p65 subunit. Transfection of small interfering RNAs targeting p65 strongly inhibited NF-B expression and activation, induced cell cycle arrest and cell death, and further sensitized HNSCC cells when combined with HDIs. The p65 small interfering RNA inhibited HDI-enhanced expression of several NF-B–inducible genes implicated in oncogenesis of HNSCC, such as p21, cyclin D1, and BCL-XL. Bortezomib, an inhibitor of proteasome-dependent NF-B activation, also increased sensitization to trichostatin A, sodium butyrate, and a novel HDI, PXD101, in vitro, and to the antitumor effects of PXD101 in bortezomib-resistant UMSCC-11A xenografts. However, gastrointestinal toxicity, weight loss, and mortality of the combination were dose limiting and required parenteral fluid administration. We conclude that HDI-enhanced NF-B activation is one of the major mechanisms of resistance of HNSCC to HDIs. The combination of HDI and proteasome inhibitor produced increased antitumor activity. Low starting dosages for clinical studies combining HDIs with proteasome inhibitors and IV fluid support may be warranted. [Mol Cancer Ther 2007;6(1):37–50]

Grant support: National Institute on Deafness and Other Communication Disorders Intramural Project Z01-DC00016.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: J. Duan and J. Friedman contributed equally as first authors to experimental work.

³ T.L. Lee, unpublished data.

⁴ Z. Chen, unpublished data.

Received 7/27/06; revised 11/ 8/06; accepted 11/20/06.

This article has been cited by other articles:

				C. Allen, K. Saigal, L. Nottingham, P. Arun, Z. Chen, and C. Van Waes Bortezomib-Induced Apoptosis with Limited Clinical Response Is Accompanied by Inhibition of Canonical but not Alternative Nuclear Factor-{kappa}B Subunits in Head and Neck Cancer Clin. Cancer Res., July 1, 2008; 14(13): 4175 - 4185. [Abstract] [Full Text] [PDF]

				C. Li, R. Li, J. R. Grandis, and D. E. Johnson Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells Mol. Cancer Ther., June 1, 2008; 7(6): 1647 - 1655. [Abstract] [Full Text] [PDF]

				Y. Dai, S. Chen, L. B. Kramer, V. L. Funk, P. Dent, and S. Grant Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells Clin. Cancer Res., January 15, 2008; 14(2): 549 - 558. [Abstract] [Full Text] [PDF]

				T. L. Lee, X. P. Yang, B. Yan, J. Friedman, P. Duggal, L. Bagain, G. Dong, N. T. Yeh, J. Wang, J. Zhou, et al. A Novel Nuclear Factor-{kappa}B Gene Signature Is Differentially Expressed in Head and Neck Squamous Cell Carcinomas in Association with TP53 Status Clin. Cancer Res., October 1, 2007; 13(19): 5680 - 5691. [Abstract] [Full Text] [PDF]